C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 314—Applications for Fda Approval to Market A New DrugSubpart C—Abbreviated Applications

21 C.F.R. § 314.95 (2026)

Notice of certification of invalidity, unenforceability, or noninfringement of a patent

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1998–2024 36citing cases
At a glance

Courts have cited this section in 36 opinions since 1998, 5 of them in the last five years. The most litigated part is subsection (c)(6) (2 cases).

(a) Notice of certification. For each patent that claims the listed drug or that claims a use for such listed drug for which the applicant is seeking approval and for which the applicant submits a paragraph IV certification, the applicant must send notice of such certification by registered or certified mail, return receipt requested, or by a designated delivery service, as defined in paragraph (g) of this section to each of the following persons:

(1) Each owner of the patent that is the subject of the certification or the representative designated by the owner to receive the notice. The name and address of the patent owner or its representative may be obtained from the U.S. Patent and Trademark Office; and

(2) The holder of the approved NDA under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the listed drug that is claimed by the patent and for which the applicant is seeking approval, or, if the NDA holder does not reside or maintain a place of business within the United States, the NDA holder's attorney, agent, or other authorized official. The name and address of the NDA holder or its attorney, agent, or authorized official may be obtained by sending a written or electronic communication to the Central Document Room, Attn: Orange Book Staff, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266 or to the Orange Book Staff at the email address listed on the Agency's Web site at http://www.fda.gov.

(3) This paragraph (a) does not apply to a method-of-use patent that does not claim a use for which the applicant is seeking approval.

(4) An applicant may send notice by an alternative method only if FDA has agreed in advance that the method will produce an acceptable form of documentation.

(b) Sending the notice. (1) Except as provided under paragraph (d) of this section, the applicant must send the notice required by paragraph (a) of this section on or after the date it receives a paragraph IV acknowledgment letter from FDA, but not later than 20 days after the date of the postmark on the paragraph IV acknowledgment letter. The 20-day clock described in this paragraph (b) begins on the day after the date of the postmark on the paragraph IV acknowledgment letter. When the 20th day falls on Saturday, Sunday, or a Federal holiday, the 20th day will be the next day that is not a Saturday, Sunday, or Federal holiday.

(2) Any notice required by paragraph (a) of this section is invalid if it is sent before the applicant's receipt of a paragraph IV acknowledgment letter, or before the first working day after the day the patent is published in the list. The applicant will not have complied with this paragraph (b) until it sends valid notice.

(3) The applicant must submit to FDA an amendment to its ANDA that includes a statement certifying that the notice has been provided to each person identified under paragraph (a) of this section and that the notice met the content requirements under paragraph (c) of this section. A copy of the notice itself need not be submitted to the Agency.

(c) Contents of a notice. In the notice, the applicant must cite section 505(j)(2)(B)(iv) of the Federal Food, Drug, and Cosmetic Act and the notice must include, but is not limited to, the following information:

(1) A statement that FDA has received an ANDA submitted by the applicant containing any required bioavailability or bioequivalence data or information.

(2) The ANDA number.

(3) A statement that the applicant has received the paragraph IV acknowledgment letter for the ANDA.

(4) The established name, if any, as defined in section 502(e)(3) of the Federal Food, Drug, and Cosmetic Act, of the proposed drug product.

(5) The active ingredient, strength, and dosage form of the proposed drug product.

(6) The patent number and expiration date of each listed patent for the reference listed drug alleged to be invalid, unenforceable, or not infringed.

(7) A detailed statement of the factual and legal basis of the applicant's opinion that the patent is not valid, unenforceable, or will not be infringed. The applicant must include in the detailed statement:

(i) For each claim of a patent alleged not to be infringed, a full and detailed explanation of why the claim is not infringed.

(ii) For each claim of a patent alleged to be invalid or unenforceable, a full and detailed explanation of the grounds supporting the allegation.

(8) If the applicant alleges that the patent will not be infringed and the applicant seeks to preserve the option to later file a civil action for declaratory judgment in accordance with section 505(j)(5)(C) of the Federal Food, Drug, and Cosmetic Act, then the notice must be accompanied by an offer of confidential access to the ANDA for the sole and limited purpose of evaluating possible infringement of the patent that is the subject of the paragraph IV certification.

(9) If the applicant does not reside or have a place of business in the United States, the name and address of an agent in the United States authorized to accept service of process for the applicant.

(d) Amendment or supplement to an ANDA. (1) If, after receipt of a paragraph IV acknowledgment letter or acknowledgment letter, an applicant submits an amendment or supplement to its ANDA that includes a paragraph IV certification, the applicant must send the notice required by paragraph (a) of this section at the same time that the amendment or supplement to the ANDA is submitted to FDA, regardless of whether the applicant has already given notice with respect to another such certification contained in the ANDA or in an amendment or supplement to the ANDA.

(2) If, before receipt of a paragraph IV acknowledgment letter, an applicant submits an amendment to its ANDA that includes a paragraph IV certification, the applicant must send the notice required by paragraph (a) of this section in accordance with the procedures in paragraph (b) of this section. If an ANDA applicant's notice of its paragraph IV certification is timely provided in accordance with paragraph (b) of this section and the applicant has not submitted a previous paragraph IV certification, FDA will base its determination of whether the applicant is a first applicant on the date of submission of the amendment containing the paragraph IV certification.

(3) An applicant that submits an amendment or supplement to seek approval of a different strength must provide notice of any paragraph IV certification in accordance with paragraph (d)(1) or (2) of this section, as applicable.

(e) Documentation of timely sending and receipt of notice. The applicant must amend its ANDA to provide documentation of the date of receipt of the notice required under paragraph (a) of this section by each person provided the notice. The amendment must be submitted to FDA within 30 days after the last date on which notice was received by a person described in paragraph (a) of this section. The applicant's amendment also must include documentation that its notice was sent on a date that complies with the timeframe required by paragraph (b) or (d) of this section, as applicable, and a dated printout of the entry for the reference listed drug in FDA's “Approved Drug Products With Therapeutic Equivalence Evaluations” (the list) that includes the patent that is the subject of the paragraph IV certification. FDA will accept, as adequate documentation of the date the notice was sent, a copy of the registered mail receipt, certified mail receipt, or receipt from a designated delivery service as defined in paragraph (g) of this section. FDA will accept as adequate documentation of the date of receipt a return receipt, signature proof of delivery by a designated delivery service, or a letter acknowledging receipt by the person provided the notice. An applicant may rely on another form of documentation only if FDA has agreed to such documentation in advance. A copy of the notice itself need not be submitted to the Agency.

(f) Forty-five day period after receipt of notice. If the requirements of this section are met, FDA will presume the notice to be complete and sufficient, and it will count the day following the date of receipt of the notice by the patent owner or its representative and by the approved NDA holder or its attorney, agent, or other authorized official as the first day of the 45-day period provided for in section 505(j)(5)(B)(iii) of the Federal Food, Drug, and Cosmetic Act. FDA may, if the applicant provides a written statement to FDA that a later date should be used, count from such later date.

(g) Designated delivery services. (1) For purposes of this section, the term “designated delivery service” means any delivery service provided by a trade or business that the Agency determines:

(i) Is available to the general public throughout the United States;

(ii) Records electronically to its database, kept in the regular course of its business, or marks on the cover in which any item referred to in this section is to be delivered, the date on which such item was given to such trade or business for delivery; and

(iii) Provides overnight or 2-day delivery service throughout the United States.

(2) FDA may periodically issue guidance regarding designated delivery services.

[81 FR 69651, Oct. 6, 2016, as amended at 84 FR 6673, Feb. 28, 2019]
The 20 cases that cite 21 C.F.R. § 314.95 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENCelgene Corp. v. Mylan Pharm. Inc., 17 F.4th 1111 (Fed. Cir. 2021).
cites § 314.95 6×cited by 31 cases
Where it cites § 314.95
“; 21 C.F.R. § 314.95 (e). Indeed, the substance of the notice letter (i.”
The case’s holding
In Hatch-Waxman actions, the submission of an ANDA is the sole infringing act, and employee homes or storage lockers do not constitute a regular and established place of business.
Later courts cite it for
“corporate separateness is an issue of regional-circuit law.” · 5 citing courts
cites § 314.95 2×cited by 33 cases
Where it cites § 314.95
“” 21 C.F.R. § 314.95 (2001). This court is imposing its own independent requirement that the notice be subject to an APA proceeding.”
The case’s holding
A private party cannot enforce the Hatch-Waxman paragraph IV notice requirement in a patent infringement action; such challenges must be brought, if at all, under the Administrative Procedure Act.
Later courts cite it for
“the two acts of (1) a patentee listing a patent in the orange book through the filing of a nda, and (2) a generic manufacturer fifing an anda, together meet the case or controversy requirement so as to allow a declaratory judgment action of noninfringement.” · 1 citing court
3
GREENGalderma Labs., L.P. v. Teva Pharm. USA, Inc., 290 F. Supp. 3d 599 (N.D. Tex. 2017).
cites § 314.95 1×cited by 27 cases
Where it cites § 314.95
“21 C.F.R. § 314.95 . The NDA holder then has 45 days to file suit against the ANDA applicant for patent infringement.”
Later courts cite it for
“most district courts within this circuit have imposed the burden of proving that venue is proper on the plaintiff once a defendant has objected to the plaintiff's chosen forum.” · 11 citing courts
4
GREENBiovail Corp. Int'l v. Andrx Pharm., Inc., 239 F.3d 1297 (Fed. Cir. 2001).
cites § 314.95 1×cited by 73 cases
Where it cites § 314.95
“See 21 C.F.R. § 314.95 (2000). The obligation to inform the parties, and the trial court, as to any material amendment to the ANDA continues throughout the litigation that is artificially provoked under Paragraph IV.”
The case’s holding
Prosecution history estoppel completely bars the doctrine of equivalents when a claim amendment is made for reasons related to patentability.
Later courts cite it for
“literal infringement requires a patentee to prove by a preponderance of the evidence that every limitation of the asserted claim is literally met by the allegedly infringing device.” · 4 citing courts
5
GREENTorPharm, Inc. v. Thompson, 260 F. Supp. 2d 69 (D.D.C. 2003).
cites § 314.95 2×cited by 15 cases
Where it cites § 314.95
“at the same time that the amendment to the abbreviated application is submitted to FDA,” 21 C.F.R. § 314.95 (d) (emphasis added). TorPharm pointed this fact out to the FDA, and argued that Purepac’s failure to abide by the statute should have voided its amendment.”
Later courts cite it for
“either the applicant is seeking approval for the use claimed in the patent, or it is not.” · 2 citing courts
6
GREENFerring B v. v. Watson Labs., Inc., 764 F.3d 1401 (Fed. Cir. 2014).
cites § 314.95 1×cited by 40 cases
Where it cites § 314.95
“§ 355 (j)(2)(B)(ii) and 21 C.F.R. § 314.95 (c) regarding its proposed generic tranexamic acid product as specified in its ANDA.”
The case’s holding
A proposed generic product's ANDA specification controls infringement when it resolves whether the product meets the claims; otherwise, bioequivalence and actual sample evidence measured against the commercial product decides infringement.
Later courts cite it for
“it defines a proposed generic product in a manner that either meets the limitations of an asserted patent claim or is outside the scope of such a claim.” · 5 citing courts
7
GREENBen Venue Labs., Inc. v. Novartis Pharm. Corp., 146 F. Supp. 2d 572 (D.N.J. 2001).
cites § 314.95 2×cited by 8 cases
Where it cites § 314.95
“See 21 C.F.R. 314.95 (2000). The obligation to inform the parties, and the trial court, as to any material amendment to the ANDA continues throughout the litigation that is artificially provoked under Paragraph IV.”
8
GREENMylan Pharm., Inc. v. Thompson, 139 F. Supp. 2d 1 (D.D.C. 2001).
cites § 314.95 1×cited by 20 cases
Where it cites § 314.95
“§ 355 (j)(2)(B)(i). This notice must include a detailed statement of the factual and legal basis for the ANDA applicant’s assertion that the patent is not valid or will not be infringed by its generic product.”
9
GREENBarr Labs., Inc. v. Thompson, 238 F. Supp. 2d 236 (D.D.C. 2002).
cites § 314.95 1×cited by 20 cases
Where it cites § 314.95
“§ 366 (j)(2)(B); 21 C.F.R. § 314.95 . The FDA may approve an ANDA with a paragraph IV certification, and the approval may become effective immediately, despite the unexpired patent, unless an action for patent infringement is brought against the ANDA applicant within 45 days of…”
Later courts cite it for
“likewise, when ruling on cross-motions for summary judgment, the court shall grant summary judgment only if one of the moving parties is entitled to judgment as a matter of law upon material facts that are not genuinely in dispute.” · 5 citing courts
10
REDElan Corp., PLC v. Andrx Pharm., Inc., 272 F. Supp. 2d 1325 (S.D. Fla. 2003).
cites § 314.95 2×cited by 5 cases
Reversed in part by Andrx Pharmaceuticals v. Elan Corporation (2005): the Court of Appeals for the Eleventh Circuit's own opinion in this case ("Accordingly, the district court’s order is AFFIRMED in part, REVERSED in part, and R…
Where it cites § 314.95
“98-7164 — First Suit Directed to Andrx’s 550 mg Product On or about September 10, 1998, Elan received from Andrx a first Notice of Certification under 21 C.F.R. § 314.95 (Certification Notice), informing Elan of Andrx’s initial ANDA submission directed to Elan’s 550 mg product,…”
11
GREENSB Pharmco Puerto Rico, Inc. v. Mut. Pharm. Co., 552 F. Supp. 2d 500 (E.D. Pa. 2008).
cites § 314.95 4×cited by 2 cases
Where it cites § 314.95
“” 21 C.F.R. § 314.95 (b). Defendants argue that “[s]ub-section (I) [of 21 U.”
12
GREENDr. Reddy's Labs., Inc. v. Thompson, 302 F. Supp. 2d 340 (D.N.J. 2003).
cites § 314.95 1×cited by 12 cases
Where it cites § 314.95
“§ 355 (j)(2)(B); 21 C.F.R. § 314.95 . The patent owner may then sue for patent infringement pursuant to § 271(e)(2), and, if the owner does so within 45 days of receiving the notice, approval of the ANDA is stayed at least thirty months from the date the owner receives notice '…”
Later courts cite it for
“be able to sell its rights to . . . exclusivity” · 2 citing courts
13
GREENTeva Pharm., Indus., Ltd. v. Food & Drug Admin., 355 F. Supp. 2d 111 (D.D.C. 2004).
cites § 314.95 1×cited by 12 cases
Where it cites § 314.95
“When the ANDA contains a paragraph IV certification, the applicant must also provide notice of the paragraph IV certification to the NDA holder and the patent owner, and describe the, factual and legal basis for the applicant’s opinion that an active patent is invalid or not…”
Later courts cite it for
“355(c), regulating ndas, and 355(j), regulating andas, painstakingly detail the approval process for each of the type of drugs,” · 2 citing courts
14
GREENAndrx Pharm., Inc. v. Biovail Corp., 276 F.3d 1368 (Fed. Cir. 2002).
cites § 314.95 1×cited by 11 cases
Where it cites § 314.95
“§ 355 (j)(2)(B)(i); 21 C.F.R. § 314.95 (c)(6). The patentee then has forty-five days to sue the ANDA applicant for patent infringement, and the ANDA applicant may not file a declaratory judgment during this time (based on the filing of the ANDA application).”
The case’s holding
A district court may shorten the statutory thirty-month stay of FDA approval only if a party fails to reasonably cooperate in expediting the patent infringement action.
Later courts cite it for
“congress struck a balance between two competing policy interests: (1) inducing pioneering research and development of new drugs and (2) enabling competitors to bring low-cost, generic copies of those drugs to market.” · 10 citing courts
15
GREENRanbaxy Labs. Ltd. v. United States Food & Drug Admin., 307 F. Supp. 2d 15 (D.D.C. 2004).
cites § 314.95 1×cited by 8 cases
Where it cites § 314.95
“§ 355 (j)(2)(A)(vii)(I)-(IV); 21 C.F.R. § 314.95 . The FDA requires an ANDA applicant to amend its certification "if, at any time before the effective date of the approval of the application, the applicant learns that the submitted certification is no longér accurate.”
Later courts cite it for
“after the summary judgment decision, ... the court indicated to ranbaxy and pfizer the patent holder, that the court's schedule would not allow for a trial until after the january 29, 2004, expiration of the '216 patent.” · 1 citing court
16
GREENMylan Labs., Inc. v. Thompson, 332 F. Supp. 2d 106 (D.D.C. 2004).
cites § 314.95 1×cited by 7 cases
Where it cites § 314.95
“When the ANDA contains a paragraph IV certification, the applicant must also provide notice of the paragraph IV certification to the NDA holder and the patent owner, and describe the factual and legal basis for the applicant’s opinion that an active patent is invalid or not…”
17
GREENDey, L.P. v. Ivax Pharm., Inc., 233 F.R.D. 567 (C.D. Cal. 2005).
cites § 314.95 1×subsections: (c)(6)cited by 6 cases
Where it cites § 314.95
“§ 355Cj)(2)(B)(i); 21 C.F.R. 314.95(c)(6). If the NDA holder sues the ANDA applicant for patent infringement within 45 days of the notification, the FDA may not approve the ANDA until the earlier of thirty months after the patentee’s receipt of notice, expiration of the patent,…”
18
GREENMylan Pharm., Inc. v. Thompson, 268 F.3d 1323 (Fed. Cir. 2001).
cites § 314.95 1×cited by 20 cases
Where it cites § 314.95
“§ 355(j)(2)(B)(i); 21 C.F.R. § 314.95 (c)(6) (2001). The patentee is then given forty-five days to sue the ANDA applicant for infringement.”
The case’s holding
The Hatch-Waxman Amendments do not create a private right of action to delist a patent from the Orange Book or to compel FDA approval of a generic drug application.
Later courts cite it for
“an attempt to assert a private right of action for 'delisting' under the ffdca.” · 3 citing courts
19
GREENIn re '318 Pat. Infringement Litig., 578 F. Supp. 2d 711 (D. Del. 2008).
cites § 314.95 1×cited by 4 cases
Where it cites § 314.95
“§ 355 (j)(2)(B); 21 C.F.R. §§ 314.95 (e) and (f). Plaintiffs represent to the court that the 30-month stay expires on August 28, 2008 by their calculation.”
Later courts cite it for
“not finished . . . by the time the '318 patent was allowed” · 2 citing courts
20
GREENDaiichi Pharm. Co. v. Apotex, Inc., 441 F. Supp. 2d 672 (D.N.J. 2006).
cites § 314.95 1×cited by 4 cases
Where it cites § 314.95
“Daiichi was given notice by letter of Apotex’s ANDA submission pursuant to Section 505(j')(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act ( 21 CFR § 314.95 (c)) requesting marketing approval to manufacture, use or sell Oflox-acin Otic Solution, 0.”

Show all 36 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199820112024

One bar per year. Tallest: 5 cases in 2001. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.10Fed. Cir.7D.N.J.6D. Del.3S.D.N.Y.2E.D. Pa.2C.D. Cal.1D.C. Cir.1

The 8 courts with the most citing cases, of 12 courts in all.

By subsection
(c)(6)2 cases
Dey, L.P. v. Ivax Pharm., Inc., 233 F.R.D. 567 (C.D. Cal. 2005).“§ 355Cj)(2)(B)(i); 21 C.F.R. 314.95(c)(6). If the NDA holder sues the ANDA applicant for patent infringement within 45 days of the notification, the FDA may not approve the ANDA until the earlier of thirty months after the patentee’s receipt of notice, expiration of the patent,…”
(e)1 case
Melinta Therapeutics, LLC v. U.S. Food & Drug Admin., No. 2022-2190 (D.D.C. Oct. 7, 2022).

Show all 36 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com